Michael Girardi, MD, is Professor and Vice Chair of the Department of Dermatology at the Yale School of Medicine, and Director of the Yale-New Haven Hospital and Smilow Cancer Center’s Photopheresis and Phototherapy Centers. He graduated from Brown University with a combined degree with Biology and Computer Science, and received his M.D. with the Honors Thesis Award from the Yale School of Medicine. During more than 15 years leading an NCI-funded research program at Yale, his laboratory is credited with major contributions to our understanding of regulation of cutaneous immunology, cutaneous carcinogenesis, and cutaneous lymphoma. Specifically, the Girardi lab has elucidated roles for gamma-delta T cells, NKG2D ligands, and Langerhans cells in cutaneous biology and skin cancer development and progression. He actively collaborates with the Department of Biomedical Engineering on developing nanoparticle-based skin delivery systems, and the Department of Genetics to identify mutational drivers of cutaneous T cell lymphoma (CTCL). Dr. Girardi’s clinical expertise is in the treatment of CTCL, skin cancer including malignant melanoma, graft-versus-host disease (GVHD), and autoimmune disorders including lupus erythematous and scleroderma. He is an active member of the ASCI, AAD, and SID, and has published 100+ articles including in the high-impact Nature, Science, Proceedings of the National Academy of Sciences, Journal of Experimental Medicine, and the New England Journal of Medicine.